

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 30 JUNE 2024

Reference is made to the annual report (the “**2024 Annual Report**”) of Wai Chun Bio-Technology Limited (the “**Company**”), together with its subsidiaries, collectively referred to as (the “**Group**”) for the year ended 30 June 2024. Unless otherwise defined, capitalised terms used herein shall have the same meaning as those defined in the 2024 Annual Report.

In addition to the information disclosed in the note 34 headed “SHARE-BASED PAYMENTS” on pages 132 to 134 of the 2024 Annual Report, the Company would like to provide the following supplementary information to the shareholders and potential investors of the Company.

SHARE OPTION SCHEME

1. At the extraordinary general meeting of the Company held on 22 July 2015 (the “**Adoption Date**”), the scheme mandate limit for the Share Option Scheme was approved by the then shareholders to allow the Company to grant share options entitling holders thereof to subscribe for up to 15,954,685 shares, representing approximately 9.30% of the issued shares of the Company as at the date of the 2024 Annual Report;
2. The number of share options available for grant under the scheme mandate limit of the Share Option Scheme as at 1 July 2023 and 30 June 2024 was 6,996,395 and 15,954,685 respectively;
3. During the year ended 30 June 2024, 8,958,290 share options were lapsed, and no share options were granted, exercised or cancelled under the Share Option Scheme. As at 30 June 2024, there were no outstanding share options under the Share Option Scheme;
4. The Share Option Scheme, unless otherwise cancelled or amended, will remain in force for 10 years from the Adoption Date;

5. Any grant of share options to a participant who is a Director, chief executive or substantial shareholder (as defined under the Listing Rules) of the Company or their respective associates (including a discretionary trust whose discretionary objects include a Director, chief executive or a substantial Shareholder of a company beneficially owned by any Director, chief executive or substantial Shareholder) must be approved by the independent non-executive Directors (excluding an independent non-executive Director who is the grantee of the Options);
6. Where the Board proposes to grant any share option to a participant who is a substantial shareholder or an independent non-executive Director, or their respective associates (including a discretionary trust whose discretionary objects include a substantial Shareholder or an independent non-executive Director or a company beneficially owned by any substantial shareholder or independent non-executive Director) would result in the shares issued and to be issued upon exercise of all share options already granted and to be granted (including share options exercised, cancelled and outstanding) to such person in the 12-month period up to and including the date of such grant:
 - (i) representing in aggregate more than 0.1% of the total number of shares in issue; and
 - (ii) having an aggregate value, based on the closing price of the shares at the date of each grant, over HK\$5,000,000.00,

such proposed grant of share options must be approved by the shareholders in general meeting. In such a case, the Company shall send a circular to its shareholders containing all those terms as required under the Listing Rules. All connected persons of the Company must abstain from voting at such general meeting (except that any connected person may vote against the relevant resolution provided that his intention to do so has been stated in this circular). Any vote taken at the meeting to approve the grant of such share options must be taken on a poll;

7. As at 31 July 2023 and 30 June 2024, no share options were granted and to be granted to a related entity participant or service provider (as defined in the Listing Rules) in any 12-month period exceeding 0.1% of the total issued Shares; and
8. Any share option may be exercised in accordance with the terms of the Share Option Scheme and such other terms and conditions upon which a share option was granted, at any time during the option period after the share option has been granted by the Board but in any event, not longer than 10 years from the date of grant. A share option shall lapse automatically and not be exercisable (to the extent not already exercised) on the expiry of the option period. Save as determined by the Board and specified in the offer letter at the time of the offer of the share option, there is no minimum period for which a share option must be held before it can be exercised.

The information contained in this supplemental announcement does not affect the other information contained in the 2024 Annual Report. Save as disclosed in this announcement, all the other information and contents in the 2024 Annual Report remain unchanged.

By Order of the Board
Wai Chun Bio-Technology Limited
Lam Ka Chun
Chairman and Chief Executive Officer

Hong Kong, 2 October 2025

As at the date of this announcement, the Board comprises:

Executive Director:

Mr. Lam Ka Chun (*Chairman and Chief Executive Officer*)

Independent Non-executive Directors:

Mr. Wong Po Keung

Mr. Wang Ziniu

Ms. Xu Huiling